Prempro Insider Trading Case Focuses On Sales Reps
A Securities & Exchange Commission settlement with two Wyeth sales representatives over alleged insider trading illustrates the complexities of coordinating the release of government-sponsored studies on prescription drugs
You may also be interested in...
FDA is considering hormone replacement therapy class labeling that would incorporate data from a WHI sub-study showing twice the rate of dementia in patients taking Wyeth's Prempro estrogen/progestin combo
The National Institutes of Health can improve its methods for releasing study data, Women's Health Initiative Director Barbara Alving, MD, said
Wyeth is sending letters to approximately 550,000 physicians as part of a Prempro risk management program to address risks associated with use of the hormone combination for cardiovascular disease and osteoporosis prevention